Industry Overview

US digital pathology market was valued at $515.5 million in 2025 and is projected to reach $3,387.5 million by 2035, growing at a CAGR of 20.8% during the forecast period (2026–2035). The US digital pathology market is expanding steadily as healthcare systems accelerate the shift toward image-based diagnostics and AI-supported analysis. Growth is reinforced by the rising demand for efficient pathology workflows, particularly as hospitals confront increasing case volumes and a shortage of trained pathologists. Pharmaceutical and biotechnology companies are also adopting digital platforms to support research, biomarker studies, and drug-development programs. Advancements in whole-slide imaging, cloud storage, and machine learning are improving accuracy and shortening turnaround times. Strong investment from established technology providers and emerging digital health firms continues to strengthen market competitiveness. Together, these factors are shaping a robust environment for digital pathology adoption across clinical and research settings in the United States.

Market Dynamics

Growing Integration of AI for Diagnostic Support

The US market is witnessing a steady rise in AI-driven tools that enhance slide interpretation and streamline workflow management. Hospitals and diagnostic laboratories are adopting automated image-analysis platforms to improve precision and reduce review times for complex cases. This shift is supported by strong regulatory momentum, with more algorithms receiving approvals for clinical use. Leading developers are expanding their portfolios to address cancer diagnostics, quantification tasks, and early disease detection. The growth of cloud-enabled systems is further accelerating real-time collaboration between pathologists and specialists. As a result, AI has become a core driver of operational efficiency and diagnostic accuracy across U.S. pathology practices.

Expansion of Digital Platforms in Drug Development

Biopharmaceutical companies in the US are increasingly incorporating digital pathology into research and preclinical workflows. Adoption is rising as high-resolution imaging and automated data analysis offer clearer insights into tissue behavior and treatment response. Key industry players are forming partnerships with technology providers to centralize research data and support large-scale studies. The demand for reproducible and quantifiable analysis is also pushing organizations to transition from manual microscopy to digital workflows. Enhanced integration with cloud storage and laboratory information systems is enabling seamless data sharing across research teams. This trend is strengthening the role of digital pathology as a cornerstone in modern drug discovery and translational research.

Market Segmentation

• Based on the product, the market is segmented into scanner device, software and storage system.
• Based on the application, the market is segmented into teleconsultation, disease diagnosis, and drug discovery and other.
• Based on the end-user, the market is segmented into biotechnology & pharmaceutical companies, hospitals and others.

Software Platforms Strengthening Their Position as the Leading Product Category

Software solutions remain the most influential segment in the US digital pathology landscape, driven by their central role in image management, automated analysis, and workflow coordination. Adoption is accelerating as hospitals and diagnostic centers prioritize platforms that enhance reporting accuracy and support interoperability with existing laboratory systems. Companies such as Proscia, Indica Labs, and Roche continue to introduce advanced analytical tools designed to manage large slide volumes and assist with complex case reviews. Recent upgrades in cloud-based storage and AI integration are further improving system reliability and turnaround times. Growing emphasis on remote collaboration is also reinforcing demand for robust software ecosystems. This segment’s dominance is expected to persist as digital workflows become standard practice across clinical settings.

Drug Discovery Emerging as a High-Growth Application Area

Drug discovery is gaining momentum as one of the fastest-growing use cases in the US digital pathology market, supported by rising investment in preclinical research and biomarker development. Pharmaceutical companies are adopting digital imaging and automated quantification tools to streamline study reproducibility and accelerate decision-making. Key contributors include firms such as Akoya Biosciences, Visiopharm, and Paige, which are offering specialized platforms for spatial analysis and high-throughput research. Recent trends highlight a shift toward integrating imaging data with multi-omics and AI-driven models to enhance predictive insights. Improved data-sharing frameworks and advanced cloud infrastructures are enabling large research teams to conduct coordinated analyses. This expansion reflects the sector’s strategic move toward more data-intensive and technology-driven research workflows.

Market Players Outlook

The major companies operating in the US digital pathology market include F. Hoffmann-La Roche Ltd., Leica Biosystems, Nussloch GmbH, Philips N.V., Hamamatsu Photonics K.K., and Indica Labs LLC, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In September 2025, Labcorp announced collaboration with Roche to implement the company's FDA-cleared VENTANA DP 600 and DP 200 slide scanners. The investment enables pathologists to diagnose patients using digital images and supports future artificial intelligence (AI) integration.

• In July 2025, PathAI unveiled the launch of the Precision Pathology Network (PPN) powered by PathAI’s AISight 1 Image Management System (IMS). The PPN is designed to enable early access to the latest AI-powered pathology solutions developed by PathAI in collaboration with the biopharma industry, enable participating laboratories to monetize real-world pathology data, support biopharma sponsored evidence generation studies, and enable novel clinical development strategies leveraging AI-pathology.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the US digital pathology market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.